James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Exxon Mobil Corporation (XOM) Accounting Probe Is Much Ado About Nothing

Exxon Mobil Corporation shareholders see concerning headlines today, but the suggestions are far more bite than bark for XOM stock.

S&P 500: Interest Rates Are Just an Excuse

The S&P 500 and other U.S. stock indices are hanging by a thread -- but not the thread you think it is. In fact, THAT thread is just an excuse.

Why Deutsche Bank AG (USA) (DB), Cabot Oil & Gas Corporation (COG) and Oracle Corporation (ORCL) Are 3 of Today’s Worst Stocks

The trading week couldn't end soon enough for owners of Deutsche Bank (DB), Cabot (COG) and Oracle (ORCL) stock.

Apple Inc. Is About to Disappoint Everyone (AAPL)

Apple stock (AAPL) has soared on the initial euphoria of the iPhone 7. But anyone familiar with Apple history should know this smells funny.

Why Monsanto Company (MON), Sarepta Therapeutics Inc (SRPT) and VF Corp (VFC) Are 3 of Today’s Worst Stocks

The bullish wave didn't carry Monsanto Company (MON), VF (VFC) and Sarepta Therapeutics (SRPT) with it. Here's what traders need to know.